Advanced engineering of third-generation lysins and formulation strategies for clinical applications by De Maesschalck, Vincent et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=imby20
Critical Reviews in Microbiology
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/imby20
Advanced engineering of third-generation lysins
and formulation strategies for clinical applications
Vincent De Maesschalck , Diana Gutiérrez , Jan Paeshuyse , Rob Lavigne &
Yves Briers
To cite this article: Vincent De Maesschalck , Diana Gutiérrez , Jan Paeshuyse , Rob Lavigne &
Yves Briers (2020): Advanced engineering of third-generation lysins and formulation strategies for
clinical applications, Critical Reviews in Microbiology, DOI: 10.1080/1040841X.2020.1809346
To link to this article:  https://doi.org/10.1080/1040841X.2020.1809346
© 2020 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 04 Sep 2020.
Submit your article to this journal 
Article views: 429
View related articles 
View Crossmark data
REVIEW ARTICLE
Advanced engineering of third-generation lysins and formulation strategies
for clinical applications
Vincent De Maesschalcka,b , Diana Gutierrezb , Jan Paeshuysea , Rob Lavignea and Yves Briersb
aDepartment of Biosystems, KU Leuven, Leuven, Belgium; bDepartment of Biotechnology, Ghent University, Gent, Belgium
ABSTRACT
One of the possible solutions for the current antibiotic resistance crisis may be found in (often
bacteriophage-derived) peptidoglycan hydrolases. The first clinical trials of these natural enzymes,
coined here as first-generation lysins, are currently ongoing. Moving beyond natural endolysins
with protein engineering established the second generation of lysins. In second-generation lysins,
the focus lies on improving antibacterial and biochemical properties such as antimicrobial activ-
ity and stability, as well as expanding their activities towards Gram-negative pathogens.
However, solutions to particular key challenges regarding clinical applications are only beginning
to emerge in the third generation of lysins, in which protein and biochemical engineering efforts
focus on improving properties relevant under clinical conditions. In addition, increasingly
advanced formulation strategies are developed to increase the bioavailability, antibacterial activ-
ity, and half-life, and to reduce pro-inflammatory responses. This review focuses on third-gener-
ation and advanced formulation strategies that are developed to treat infections, ranging from
topical to systemic applications. Together, these efforts may fully unlock the potential of lysin
therapy and will propel it as a true antibiotic alternative or supplement.
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As was anticipated by sir Alexander Fleming after he
discovered penicillin, it did not take long for bacteria to
develop resistance against antibiotics (Fleming 1945).
The excessive use and misuse of antibiotics in both live-
stock and medical fields have accelerated this process,
giving rise to so-called superbugs (WHO 2015; O’Neill
2016). It is estimated that 700,000 deaths worldwide
are attributed to infections by antibiotic-resistant
pathogens each year (O’Neill 2016). As a consequence,
substantial economic losses are suffered (O’Neill 2016;
Cassini et al. 2019; Centers for Disease Prevention and
Control 2019). We have entered a post-antibiotic era
where certain bacterial pathogens are difficult to com-
bat (Centers for Disease Prevention and Control 2019).
The economic and financial risks associated with
developing new antibacterials have hamstrung the
interest of the pharmaceutical sector. Almost all antibi-
otics used today were discovered between 1940 and
1960, or are derivatives of those compounds (Lewis
2013). However, due to the alarming reports concerning
antibacterial resistance and a broad societal need, inter-
est in developing antibacterials is re-emerging, primar-
ily in academia and in small and medium-sized
companies (WHO 2015; O’Neill 2016; WHO 2017;
Theuretzbacher et al. 2020). Currently, antibacterials in
the clinical pipeline mainly comprise derivatives or
combinations of previously existing classes of antibiot-
ics. However, innovative strategies have entered the
(pre)clinical pipeline, holding the promise for entirely
new approaches to overcome the current challenges
(Theuretzbacher et al. 2019, 2020). These approaches
target virulence and involve antibodies or vaccines, but
there is also interest in bacteriophages and their com-
ponents (Theuretzbacher et al. 2020).
Bacteriophages, phages, are viruses that infect bac-
teria. These viruses encode peptidoglycan degrading
enzymes, essential for their infection cycle. First, phages
carry so-called virion-associated peptidoglycan hydro-
lases (VAPGHs) as part of their viral particles. VAPGHs
locally hydrolyze the bacterial cell wall, allowing the
phage to inject its genetic material (Moak and Molineux
2004). Secondly, phages require endolysins, expressed
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inside the bacterial host, at the end of their infection
cycle. Membrane permeabilizing holins create access
for these endolysins that consequently break down the
host peptidoglycan, leading to cell lysis and release of
the progeny phage particles (De Smet et al. 2017).
At the beginning of this millennium, the first gener-
ation of lysins, natural lysins, were explored as antibac-
terials (Figure 1). These peptidoglycan degrading
enzymes were found to have strong antibacterial activ-
ity against Gram-positive pathogens when applied
extracellularly (Nelson et al. 2001; Jado et al. 2003;
Loeffler et al. 2003). These findings marked lysins as a
promising alternative class of new antibacterials
(Czaplewski et al. 2016). Indeed, some of these first-gen-
eration lysins are currently being tested in clinical trials.
Particularly, CF-301 is the first lysin to have entered a
phase III clinical trial, targeting Staphylococcus aureus in
patients with bloodstream infections and/or right-sided
infectious endocarditis (ClinicalTrials.gov, NCT04160468).
In the case of Gram-negative bacteria, the peptidoglycan
layer is shielded by an outer membrane (OM).
Nonetheless, some natural lysins were reported to have
limited antibacterial activity when applied extracellularly
(Morita et al. 2001; Lai et al. 2011; Wu et al. 2019; Kim
et al. 2020). Orito and co-workers hypothesized this
effect is related to the presence of an amphipathic C-ter-
minal region that is responsible for a local OM perme-
abilization, granting access to the peptidoglycan layer
(Orito et al. 2004).
Insights in endolysins structural biology revealed
many endolysins have a modular design, comprising at
least one enzymatically active domain (EAD) as well as
one cell wall binding domain (CBD) (Gerstmans et al.
2018). This modular structure served as a critical basis
for the second generation of lysins, defined by the
implementation of protein engineering techniques,
moving beyond natural endolysins (Figure 1). These
lysins were engineered to improve intrinsic antibacterial
and biochemical parameters including bactericidal
activity, specificity, protein stability, and solubility.
Numerous efforts have been undertaken, including site-
directed mutagenesis, truncation of lysins, domain shuf-
fling approaches, and fusions with peptides to enhance
the above-mentioned parameters, as reviewed recently
by Gerstmans and colleagues (Gerstmans et al. 2018).
One of the main drawbacks of natural (first-generation)
lysins was their limited activity towards Gram-negative
pathogens. To overcome this barrier, outer membrane
permeabilizing peptides were fused to endolysins, as first
demonstrated in so-called ArtilysinsVR . These fusion pro-
teins proved highly effective against different Gram-
negative bacteria including Pseudomonas aeruginosa and
Acinetobacter baumannii, both in vitro, ex vivo, in vivo
and against metabolically inactive cells such as persisters
(Briers, Walmagh, Grymonprez, et al. 2014; Briers,
Walmagh, Van Puyenbroeck, et al. 2014; Defraine et al.
2016). Yet another approach to overcome the OM is
inspired by bacteriocins. The fusion of the T4 lysozyme
with the region of the toxin pesticin exploiting a TonB-
dependent translocation resulted in the specific killing of
pathogenic strains of Escherichia coli and Yersinia species
(Lukacik et al. 2012). A similar strategy resulted in the
development of so-called lysocins. In this strategy, coli-
cin-like bacteriocins were modified to comprise a lysin-
derived lytic domain to cross the OM exploiting TolC
and TolB translocation pathways. This approach was
shown to be effective against Pseudomonas aeruginosa
both in vitro and in vivo (Heselpoth et al. 2019).
Figure 1. Overview of recent advances in engineering and formulation strategies in the lysin field. First-generation lysins consti-
tute native, wild type lysins such as CF-301 and Cpl-1, of which the first one is currently being validated in a phase three clinical
trial. Initial lysin engineering studies focused on improving antibacterial and biochemical properties such as an increased bacteri-
cidal activity, a better stability, or activity towards Gram-negative pathogens (second generation). A third generation of lysins
aims to improve pharmacokinetics and/or pharmacodynamics for optimal implementation of pharmaceutical applications.
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These protein engineering efforts often relied on
traditional restriction-ligation cloning methods, which
are after all cumbersome procedures, limiting the num-
ber of engineered variants that can be studied, within a
rational design framework. The largest libraries
obtained with lysins are in the range of hundreds of
variants (Briers, Walmagh, Van Puyenbroeck, et al. 2014;
Verbree et al. 2017; Yang et al. 2017). Recent advances
now allow us to efficiently assemble tens to hundreds
of thousands of engineered proteins using efficient
assembly. A recently introduced technique dedicated to
the modular assembly of large lysin libraries is the
VersaTile technique. As proof of concept, a lysin was
engineered and selected from a library of 9576 variants
to kill clinically relevant A. baumannii strains in serum
conditions (Gerstmans et al. 2020). Implementing such
approaches can take lysin engineering to the next level
with libraries of increasing complexity. By screening
these variants for the desired traits, insights in struc-
ture-activity relationships can be gained to inspire the
construction of more refined libraries in an itera-
tive manner.
Whereas the initial engineering efforts were mainly
focussed on antibacterial and biochemical properties of
lysins that can be easily evaluated in vitro (second-gen-
eration lysins), an increasing number of lysins are being
developed to improve pharmacokinetic and/or pharma-
codynamic properties relevant under clinical conditions.
This branch of lysin engineering is only in its infancy
and includes engineering efforts to reduce unwanted
effects upon clinical administration. Examples of
unwanted effects may include immune responses to
the lysin upon (systemic) administration, a limited half-
life, and proteolysis on the site of infection due to the
presence of inflammatory proteases (Agren et al. 2000;
Jado et al. 2003; Harhala et al. 2018). These engineering
approaches include both protein engineering and bio-
chemical modifications through covalent attachment of
specific groups. Efforts focussing on tackling these hur-
dles form a basis for what we can consider a third gen-
eration of lysins (Figure 1).
Apart from this first trend of increasingly advanced
engineering efforts, a second trend in the field is the
increasing attention for the advanced formulation of
lysins to increase the bioavailability, antibacterial activ-
ity, and half-life, and to reduce pro-inflammatory
responses. Depending on the location of the infection
in the human body, specific challenges have to be over-
come. Within that context, this review will discuss
recent advances and efforts made in the field of third-
generation lysins and advanced formulation strategies
for clinical applications, outlining external and topical
uses and the path towards internal and systemic appli-
cations. A general overview of the engineering and for-
mulation approaches can be found in Figure 2 and
Table 1 for the main body sites of infection.
Topical applications
The skin is the first protective barrier shielding the
body from the external environment. Keratinocytes, the
main cell type in the epidermal layer of the skin, are
closely joined together by tight junctions to avoid pas-
sage of micro-organisms such as bacteria, viruses, or
parasites (Heath and Carbone 2013). Furthermore, these
keratinocytes also produce antimicrobial peptides
(AMPs) such as b-defensins to avoid pathogens from
entering the human body via the skin (Gallo and
Hooper 2012). Highly specialized secretory structures
such as eccrine glands and sebocytes extend the spec-
trum of AMPs but also interact with the adaptive
immune system making the skin a highly efficient first
defence line against pathogens (Gallo and Hooper
2012; Heath and Carbone 2013). However, injuries or
hypersensitivity reactions will disrupt this barrier, pro-
viding (opportunistic) pathogens access to the
human body.
Skin and soft tissue infections are highly prevalent
affecting more than 14 million people in the United
States, and are more prevalent than the number of
urinary tract infections or pneumonia (Hersh et al. 2008;
Miller et al. 2015). Furthermore, it is estimated that at
least 60% of all severe burn wounds become infected
by opportunistic pathogens (Diederen et al. 2015). In
many skin-related infections, prominent opportunistic
pathogens are Staphylococci, known for their drug
resistance (Otto 2009; Diederen et al. 2015; Park et al.
2017; Shahbazian et al. 2017). In general, infections
with methicillin-resistant S. aureus (MRSA) yearly causes
10,600 deaths in the United States and is therefore pri-
oritized by both the WHO and the CDC as a pathogen
with high priority to develop new drugs (WHO 2017;
Centers for Disease Prevention and Control 2019).
Gram-negative bacteria including P. aeruginosa, A. bau-
mannii, and Enterobacteriaceae also play an important
role in the morbidity of (burn) wound infections (Park
et al. 2017; Backes et al. 2018; Jabbour et al. 2020).
These opportunistic pathogens are known for their
emerging multi-drug resistance (WHO 2017; Centers for
Disease Prevention and Control 2019; Jabbour et al.
2020). As a result, there is an urgent need to develop
tailored approaches to combat skin infections. Third-
generation engineering or formulation strategies tar-
geting S. aureus have been extensively applied and will
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be discussed here. Although other (Gram-negative)
pathogens frequently occur as well in these types of
infections, to our knowledge no third-generation engin-
eering or formulation strategies have been made public
to date.
Proof-of-concept studies of third-generation lysins
targeting intracellular bacteria
S. aureus can invade eukaryotic cells such as keratino-
cytes, where they persist and proliferate. Since these
cells have reduced metabolic activity, they are more tol-
erant to antibiotics, rendering standard of care antibiot-
ics ineffective (Soong et al. 2015; Leimer et al. 2016;
Peyrusson et al. 2020). Yet, lysins have shown to be
effective against persister cells, since their mode-of-
action does not require an active metabolism (Briers,
Walmagh, Grymonprez, et al. 2014; Gutierrez et al.
2014; Defraine et al. 2016). In a first attempt to target
intracellular S. aureus with lysins, Becker and colleagues
fused lysostaphin, LysK, and triple-acting chimeric lysins
(K-L and L-K) to eleven different cell-penetrating pepti-
des (CPPs) (Becker et al. 2016). Lysostaphin is a peptido-
glycan-degrading enzyme secreted by Staphylococus
simulans, whereas the chimeric lysins K-L and L-K con-
sist of the lytic domains of LysK and the N-terminal
enzymatic domain of lysostaphin, but in opposite orien-
tation (Becker et al. 2016). Some fusion proteins of CPPs
to lysostaphin cause a significant reduction in intracel-
lular cell counts when tested in a bovine mammary epi-
thelial cell line (MAC-T) even though the enzymatic
activities were reduced upon fusion. On the contrary,
the addition of a CPP to LysK or the chimeric lysin L-K
did not result in enhanced intracellular killing.
Surprisingly, the chimeric lysin K-L already had the cap-
acity to kill intracellular S. aureus without a CPP. In a
Figure 2. Overview of third-generation engineering approaches and advanced formulation strategies. Increasingly advanced
engineering efforts are undertaken and advanced formulation strategies are investigated to push the development of lysins as
antibacterials. This third generation of lysins aims to improve pharmacokinetics and/or pharmacodynamics with the bulk of the
efforts focused on topical, systemic, pulmonary and gastro-intestinal applications. In addition, lysins are also investigated to coat
catheter and implant surfaces.
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next step, Becker and colleagues tested the efficacy of
their approach in a murine mastitis model. In contrast
to what was observed in cultured mammary cells, lysos-
taphin alone already resulted in a significant decrease
of the bacterial load, which was not further enhanced
by a CPP, whereas the chimeric lysin K-L lost its intracel-
lular killing activity, which was restored by fusing to a
CPP, pinpointing the complexity of CPP-mediated
uptake in eukaryotic cells (Wang et al. 2018).
Wang and colleagues also exploited the transducing
activity of CPPs (Wang et al. 2018). Three different CPPs
were fused to the N- or C-terminus of JDlys, an endoly-
sin originating from phage JD007 infecting S. aureus.
Only the N-terminal fusions were observed to retain
antibacterial activity, with fusion to the trans-activating
transcription factor of HIV type 1 (CPPTat-JDlys) being
the most active combination. Using HaCaT keratino-
cytes, a significantly increased antibacterial effect
against intracellular MRSA USA300 was observed. The
potential of this fusion approach was further evaluated
in a mouse model of cutaneous abscesses. Treatment
with CPPTat-JDlys had a better clinical outcome than
JDlys, which was also active in vivo. The abscess size
was substantially smaller and the bacterial load was
approximately 10-fold lower when comparing CPPTat-
JDlys and JDlys. The pro-inflammatory cytokine levels
(IL-6, TNF-a) are significantly decreased when treating
with CPPTat-JDlys compared to the untreated group.
This approach was further refined in a study by
R€ohrig et al. (R€ohrig et al. 2020) by selecting first the
most active lysins under intracellular and lysosomal
conditions from a library comprising 322 native, recom-
binantly engineered or truncated lysins. Then, N-ter-
minal fusions of the seven most active lysins to six
different CPPs were prepared. Whereas all JDlys-CPP
fusions were inactive in the study of Wang, lysin-CPP
combinations retained antibacterial activity in the work
of R€ohrig and colleagues (Wang et al. 2018; R€ohrig et al.
2020). They also observed that the trans-activating tran-
scription factor of HIV type 1 (Tat) has the least detri-
mental effect on the in vitro antibacterial activity. Then,
uptake and antibacterial activity of selected Tat-fusion
proteins were confirmed in three different cell lines
originating from lung epithelia (A549), mice-derived
Table 1. Overview of the third-generation engineering and advanced formulation strategies discussed in this review.




Topical Fusion to CPP to target intracellular S. aureus (Becker et al. 2016; Wang et al.
2018; R€ohrig et al. 2020)
LysGH15 Topical Co-formulation with anti-inflammatory flavonoid in
AquaphorVR gel
(Cheng et al. 2018)
Lysostaphin Topical Formulation in chitosan-protein sponges (Szweda et al. 2014)
Lysostaphin Musculoskeletal Formulation in a PEG-hydrogel (Johnson et al. 2018)
LysKCHAP Topical Co-formulation with lysostaphin in a
thermoresponsive PNIPAM gel
(Hathaway et al. 2017)
Lysostaphin Topical Formulation in an antimicrobial chitosan gel (Nithya et al. 2018)
Lysostaphin Topical Formulation in nano-emulgels (Nour El-Din et al. 2020)
T4 lysozyme
Hen egg-white lysozyme
Topical Immobilisation on cellulose nanoparticles (Abouhmad et al. 2017)
Lysostaphin Topical Coating on liposomes containing standard of care
antibiotics
(Hajiahmadi et al. 2019)
T4 lysozyme Topical Fusion to cellulose-binding module for
immobilisation on bandages
(Abouhmad et al. 2016)
Lysostaphin Topical Covalent linkage to cellulose fibres (Miao et al. 2011)
Lysostaphin Catheter Coating on plastic surfaces (polystyrene and FEP) (Shah et al. 2004; Yeroslavsky
et al. 2015)
Lysostaphin Implant Coating on titanium implants (Windolf et al. 2014)
PlySs2
SAL-1
Implant/catheter Immobilisation on self-assembling spider
silk proteins
(Nileb€ack et al. 2019; Seijsing
et al. 2020)
Cpl-1 Pulmonary Aerosolization (Doehn et al. 2013)
Cpl-1 Pulmonary Loading in chitosan nanoparticles (Gondil et al. 2020)
CP25L
SagA
Gastro-intestinal Probiotic secreting lysin (Gervasi et al. 2014;
Hang et al. 2016)




Systemic PEGylation to prolong half-life (Walsh et al. 2003; Resch et al.
2011b; Gokarn et al. 2012)
Lysostaphin Systemic Glycosylation to prolong half-life (Huang et al. 2013)
Lysostaphin
CF-301
Systemic T-cell epitope depletion to prolong half-life (Blazanovic et al. 2015; Zhao et al.
2015; Schuch et al. 2018)
Cpl-1
Lysostaphin




Systemic Fusion to an albumin binding domain to prolong
half-life
(Becker et al. 2009; Grishin, Shestak,
et al. 2019)
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fibroblasts (3T3-L1) and bone fibroblasts (MG-63). All
tested proteins were found to be noncytotoxic. As the
last step, a murine subcutaneous abscess model was
used to successfully confirm the potential of selected
Tat-engineered lysins. Moreover, by using a cocktail
of Tat-engineered enzymes targeting different peptido-
glycan bonds, a synergistic effect was observed in vivo,
indicating an optimal strategy to target intracellular S.
aureus (R€ohrig et al. 2020).
In this study, promising results are thus obtained by
selecting the right (engineered) lysin, peptide, and
cocktail. Nevertheless, these studies also show the diffi-
culties of rational engineering, exemplified by the
diverse effects when fusing a peptide to an enzyme
and the discrepancy between in vitro and in vivo data.
The eventual outcome of fusions is therefore difficult to
predict, partially due to the fact that exact mechanisms
in which proteins can overcome the eukaryotic mem-
brane are still not completely understood. In addition,
some lysins have the capacity of crossing eukaryotic
membranes without a fused peptide, such as the chi-
meric lysin K-L described above (Becker et al. 2016) and
lysin PlyC active against Streptococcus pyogenes (Shen
et al. 2016).
Advanced formulation strategies: towards
integrated topical delivery strategies of lysins
Besides engineering efforts, several advanced formula-
tion strategies have been explored to improve the top-
ical effect of lysins. These strategies have been mainly
applied to first-generation lysins and the bacteriocin
lysostaphin. Formulation strategies take other aspects
related to infection into account such as inflammation
or aim to increase the antibacterial effect of the lysin.
To address the first issue, one may co-formulate lysins
with anti-inflammatory compounds. For example, a
native lysin, LysGH15 was incorporated in an
AquaphorVR gel together with apigenin, a plant-derived,
anti-inflammatory flavonoid (Duthie and Crozier 2000;
Byun et al. 2013; Lopez-Jornet et al. 2014; Li et al. 2015;
Cheng et al. 2018). The efficacy of this treatment was
assessed in a murine skin infection model. Gels contain-
ing the lysin showed an accelerated wound healing.
When apigenin was included, levels of pro-inflamma-
tory cytokines (TNF-a, IL-1b, and IFN-c) were reduced.
Yet, the latter observation did not result in increased
wound healing. After wound healing, serum was col-
lected and revealed the presence of antibodies against
LysGH15. The development of antibodies did not sig-
nificantly affect the antibacterial activity of the lysin
(Cheng et al. 2018). Another strategy uses chitosan-
protein sponges loaded with lysostaphin as a wound
dressing material. These sponges gradually release the
lysin over a 90-min time frame. Depending on the
amount of cross-linking agent used, the level of lysin
release varied between 30 and 90% of the total amount
of lysin applied. This approach was characterized by a 6
months shelf life at 4 C (Szweda et al. 2014). Another
study applied a hydrogel consisting of polyethylene
glycol (PEG) as a polymer, loaded with lysostaphin. This
formulation strategy is not only applicable to topical
applications but for more invasive applications as well
(Johnson et al. 2018). One may also consider thermores-
ponsive polymers. Upon infection, skin temperature
increases, as was observed in chronic leg ulcers
(Fierheller and Sibbald 2010). A Poly(N-isopropylacryla-
mide) (PNIPAM) gel was loaded with a cocktail compris-
ing the cysteine, histidine-dependent aminohydrolase/
peptidase (CHAP) domain of the endolysin of phage K
and lysostaphin. A temperature increase successfully
triggered their release (Hathaway et al. 2017). These
gels may also contain preservatives such as benzalko-
nium chloride to prolong shelf-life as was patented
recently (Vladimirovna et al. 2020).
Strategies to increase the antibacterial effect by for-
mulation include the loading of a lytic enzyme in an
antibacterial matrix and a system for prolonged lysin
delivery. To address the first concept, lysostaphin was
formulated in an antimicrobial chitosan gel. In this case,
no cytotoxicity was observed against Drosophila mela-
nogaster nor against the macrophage RAW 264.7 cell
line (Nithya et al. 2018). A way to extend the lysin deliv-
ery at the site of infection involves formulation in nano-
emulgels. These thermodynamically stable particles
show good adhesion to the skin, which in turn leads to
an increased bioavailability (Tayeb and Sainsbury 2018).
The bacteriocin lysostaphin has already been formu-
lated in such nano-emulgels, resulting in a prolonged-
release up to 8 h. A treatment regimen including a top-
ical application thrice a day was sufficient to cure 48 h
old murine MRSA 300 infected skin abscesses, initially
inoculated with 3 107 CFU (Nour El-Din et al. 2020).
Notwithstanding the fact that lysostaphin is a bacteri-
ocin, similar applications could be envisioned using
phage-derived lysins or engineered lysins. Yet another
interesting nanocarrier is cellulose. This relatively cheap
material is an abundant alternative to nano-emulsions
(Habibi et al. 2010). A proof-of-concept was provided
by immobilizing T4 lysozyme and hen egg-white lyso-
zyme on these nanocarriers. These cellulose nanopar-
ticles expanded the range of pathogens that could be
targeted and increased the antibacterial effect of the
lysin (Abouhmad et al. 2017). Moreover, cellulose
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nanocarriers were shown to be non-cytotoxic, confirm-
ing their potential as a safe administration strategy
(Jackson et al. 2011). Other than using nanoparticles,
lytic enzymes may also be used to coat liposomes con-
taining standard of care antibiotics, as has been shown
for the combination of lysostaphin and vancomycin
that resulted in a powerful synergistic treatment against
MRSA (Hajiahmadi et al. 2019). Conventional formula-
tion techniques such as incorporation in gels, creams or
sprays may also be explored but may impact the
enzymatic activity of the (engineered) lysin, and also
change some critical physicochemical characteristics
such as pH and viscosity as previously observed for
such formulations of proteases (Yudanova and
Reshetov 2006). An alternative approach relies on
engineering of the lysin. Since most wound dressing
materials contain cellulose, T4 lysozyme was anchored
to cellulose using a cellulose-binding module. This
module originates from bacterial and fungal cellulases
to efficiently bind cellulose (Shoseyov et al. 2006). The
fusion of a cellulose-binding module from Cellulomonas
fimi to the T4 lysozyme resulted in immobilization of
5.5 mg protein/mg of bandage without being leached
out by washing. Although the enzymatic activity of this
lysin was lowered by the fusion, E. coli counts were
reduced by 1.59 log units (Abouhmad et al. 2016).
Besides using a cellulose-binding domain, also linkage
chemistry can be used to functionalize cellulose fibres
with lysins. Miao and colleagues linked lysostaphin to
three different types of cellulose fibres: a pure cellulose
fibre, a cellulose-chitosan fibre, and a cellulose-poly(me-
tylmethacrylate) fibre (Miao et al. 2011). Out of these
three, the functionalized cellulose fibre performed best,
and resulted in the complete contact-mediated killing
of a 106 CFU/mL S. aureus suspension. Additionally, no
significant cytotoxicity of these fibres was observed in a
HaCaT monolayer model (Miao et al. 2011). This
approach could be straightforwardly adapted towards
lysins active against other clinically relevant wound col-
onizers such as S. aureus and P. aeruginosa.
Furthermore, as is the case for other fusion concepts
described above, high-throughput engineering would
enable screening for the best variant from a library con-
taining various cellulose binding domains, lytic domains
or other domains of interest.
On a critical note, all of these concepts were eval-
uated in a murine in vivo model of skin infection.
However, murine skin structure significantly differs from
that of human skin. Firstly, mice have a thinner epider-
mis and dermis compared to humans. In addition, mur-
ine skin is covered with hair that is being renewed
every three weeks, whereas the hair cycle in humans
lasts up to several years (Wong et al. 2011). Wound
closure also progresses in a different manner (Zomer
and Trentin 2018), which limits the translational poten-
tial of the results obtained from this model. From all
animal skin types, porcine skin resembles human skin
the most, making them most suitable for skin and
wound research (Abdullahi et al. 2014). However, only
ex vivo pig skin models have been implemented so far
in the lysin field (Nithya et al. 2018; Gerstmans et al.
2020). Practical and financial considerations often
explain the choice for a murine model (Zomer and
Trentin 2018).
Lysin coatings for implanted devices
and catheters
Notwithstanding the fact that the introduction of non-
living materials in the human body for medical applica-
tions is successful in the majority of the cases, there is
an imminent risk of bacterial colonization (Busscher
et al. 2012). As a result, strategies to avoid colonization
on these surfaces have been developed, some of which
involve lysins. The first step in this field was taken by
immobilizing lysostaphin successfully on two different
polymers frequently used for catheters: polystyrene and
FEP (Shah et al. 2004; Yeroslavsky et al. 2015). The same
antibacterial enzyme was covalently linked to a titan-
ium plate, which was analyzed in a murine implant-
associated bone infection model. Seven days after
infection, the lysostaphin-coated implant contained a
significantly reduced bacterial load. After 28 days, com-
plete fracture healing was observed for this group
(Windolf et al. 2014). Besides lysostaphin, PlySs2 and
SAL-1 were immobilized on self-assembling spider silk
proteins, resulting in an effective antistaphylococcal
fibre (Nileb€ack et al. 2019; Seijsing et al. 2020). In add-
ition, one can target biofilm formation specifically com-
bining lysins with matrix-degrading enzymes such as
Dispersin B (Seijsing et al. 2020).
Mucosal applications
Several sites of the human body that are exposed to
the external environment are covered with the mucosal
layer as is the case for both the respiratory and the uro-
genital tract, intestinal and ocular surfaces. These sites
are hotspots for bacterial colonization and infection. No
specific engineering efforts have been undertaken to
improve the treatment of mucosa-related infections,
but advances in formulation strategies for pulmonary
and gastro-intestinal applications have been made.
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Formulation strategies delivering lysins to
pulmonary surfaces
Lysins have been evaluated to treat lung infections. A
prominent pathogen in these cases is Streptococcus
pneumoniae (Mandell 2015). One of the first lysins
described targeting S. pneumoniae is Cpl-1 (Loeffler
et al. 2003). This enzyme was aerosolized to deliver the
natural lysin deep into the lungs of mice suffering from
pneumonia. In this way, the infection was cleared, and
potentially systemic bacteraemia could be prevented.
However, treatment with aerosolized Cpl-1 resulted in a
significant increase in pro-inflammatory cytokines IL-1b
and IL-6 (Doehn et al. 2013). Another approach includes
the loading of Cpl-1 on antibacterial chitosan nanopar-
ticles (Gondil et al. 2020). This approach displayed low
cytotoxicity towards A549 lung epithelial cells.
However, an increased IgG immune response was
observed upon intranasal administration compared to
the response upon the unloaded nanoparticles or the
lysin alone. The advantage of this delivery strategy is a
gradual release of the lysin over 20 h, resulting in a lon-
ger bioavailability at the site of infection (Gondil
et al. 2020).
Designer probiotics encoding lytic enzymes
Probiotics can be engineered to target specific patho-
gens in the gut by secreting lysins. In this application,
the narrow activity of lysins is of great interest.
Selecting the appropriate lysin results in targeting the
desired pathogens, while not affecting the microbiota.
A proof-of-concept was shown in chicken. The probiotic
strain Lactobacillus johnsonii was engineered to secrete
the CP25L endolysin, targeting Clostridium perfringens
(Gervasi et al. 2014). The latter is a Gram-positive patho-
gen, able to secrete toxins resulting in food poisoning
(Lindstr€om et al. 2011). Similarly, a patent was filed
claiming the use of probiotic strains to secrete peptido-
glycan hydrolases to treat Clostridium difficile-associated
diarrhoea (Graf 2019). The latter species is the leading
cause of antibiotic-associated diarrhoea in the Western
world (Karen and John 2011). A different patent appli-
cation describes the use of the Enterococcal SagA anti-
gen with lytic activity recombinantly produced and
secreted from probiotic Lactobacilli (Hang et al. 2016).
Indeed, SagA was observed to protect Caenorhabditis
elegans against Salmonella pathogenesis (Rangan
et al. 2016).
Besides applications in the gut, the use of a probiotic
strain has also been investigated to prevent genital
tract infections. A proof-of-concept was established by
Liu and colleagues by successfully integrating a gene
coding for lysostaphin together with a signal sequence
and a pH-responsive promotor into the genome of
Lactobacillus plantarum WCFS1, a common colonizer of
the vaginal tract (Liu et al. 2011). Indeed, during men-
struation, the pH rises facilitating S. aureus proliferation
in the vaginal tract (Beller and Schweppe 1979).
Together with elevated protein, oxygen, and carbon
dioxide levels, S. aureus will produce toxins resulting in
toxic shock syndrome (Mccormick et al. 2001). Using
this engineered probiotic, S. aureus growth could be
limited, lowering the risk of developing toxic
shock syndrome.
Although the concept of equipping probiotics with
lysins is promising, engineered living therapeutics
should encode biocontainment mechanisms to prevent
the spread of recombinant DNA in the environment. To
date, only a limited number of such mechanisms have
been constructed for probiotic applications. An interest-
ing concept is the introduction of a temperature-
dependent kill switch: when leaving the body, the pro-
biotic is no longer able to proliferate (Pedrolli et al.
2019). Notwithstanding synthetic biologists have been
expanding the toolbox to engineer living therapeutics
over the past few years, important tools are still missing
resulting in challenges to engineering these strains
(Pedrolli et al. 2019). Lysins should also be carefully
selected to exclude toxicity against the producing pro-
biotic bacterium.
Systemic applications
Compared to topical and mucosa-related infections, the
treatment of systemic infections faces additional hur-
dles. Upon systemic administration of a proteinaceous
therapeutic such as lysins, the development of an
immune response is imminent, potentially affecting the
clinical outcome. Indeed, a diminished activity due to
the development of antibodies, or worse, a hypersensi-
tivity reaction resulting in anaphylaxis are critical points
of attention. Table 2 summarises the lysins evaluated in
murine bacteraemia models, including the immune
response when reported (Table 2).
Biochemical modifications and engineering to
reduce the immune response
Some studies indicate that this immune response not
necessarily leads to diminished antibacterial activity of
the lysin in acute infections (Loeffler et al. 2003; Schuch
et al. 2014; Zhang et al. 2016; Cheng et al. 2017).
However, to avoid the risk of provoking a hypersensitiv-
ity response or to avoid inhibition by antibodies, a
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number of so-called “masking” strategies have been
developed. These include PEGylation, glycosylation, and
T-cell epitope depletion and may be generally exploited
to develop third-generation lysins.
One of the first masking strategies implemented
with lysins is PEGylation. Briefly, polyethylene glycol
(PEG) molecules are covalently linked to certain amino
acid residues such as cysteine or lysine (Turecek et al.
2016). In 2003, lysostaphin was the first lytic enzyme to
be PEGylated resulting in a tenfold reduction in binding
affinity for anti-lysostaphin antibodies. However, in vitro
antibacterial activity was observed to be reduced as
well (Walsh et al. 2003). Nonetheless, a longer half-life
could compensate for this diminished activity in vivo.
PEGylation can also lead to complete inhibition of anti-
bacterial activity, as was observed with Cpl-1 (Resch et
al. 2011b). This study used cysteine-specific PEGylation,
but a different way of PEGylation such as lysin-specific
PEGylation with PEG tresylate or other commercially
available PEG reagents may affect antibacterial activity
to a lesser extent (Turecek et al. 2016). After all, some
patients develop anti-PEG antibodies as well. Recently,
a gene locus was identified to be associated with the
development of IgM antibodies against PEG (Chang
et al. 2017). This finding allows the prediction of a
potentially adverse outcome upon treatment with
PEGylated therapeutics enabling a patient-spe-
cific approach.
Glycosylation of the therapeutic protein could also
be used for masking and avoiding an immune
response. Human proteins are glycosylated, a posttrans-
lational modification in which carbohydrate molecules
are covalently bound to the polypeptide chain on spe-
cific locations. More specifically, N-glycosylation always
occurs on an Asn residue in an Asn-X-Ser/Thr sequence,
whereas O-glycosylation primarily targets Ser-, Tyr- or
Thr-residues (Hever et al. 2019). The lack of glycosyla-
tion leads to a shorter half-life, partially due to proteoly-
sis, as was observed with therapeutic erythropoietin
and IFN-a (Ceaglio et al. 2010; Kiss et al. 2010). Epitopes
generated in this proteolysis process can be presented
in MHC-complexes leading to T-cell activation, finally
leading to the production of specific antibodies by
mature B cells (Blum et al. 2013). In this regard, it is use-
ful to consider eukaryotic systems for lysin production
such as Saccharomyces cerevisiae. In contrast to E. coli,
S. cerevisiae is classified as a GRAS organism (generally
recognized as safe) by the FDA for recombinant expres-
sion of therapeutic proteins. This obviates an endotoxin
removal protocol. Although S. cerevisiae offers only a
basic set of glycosylation resulting in a more simplified
glycosylation pattern compared to humans, this limited
glycosylation could result in limited proteolysis and
hence a longer half-life (Doering et al. 2017). Other
eukaryotic systems such as Chinese hamster ovary
(CHO) cells could be used to obtain glycosylated thera-
peutics (Sola and Griebenow 2010; Clausen et al. 2017).
However, there is no guarantee for success: an attempt
to glycosylate lysostaphin rendered the bacteriocin
ineffective (Huang et al. 2013). The authors suggested
an N-glycosylated Asn residue situated in the catalytic
site to be responsible for the loss of the enzymatic
activity. Therefore, insights in lysin structure and in silico
prediction of glycosylation sites could potentially give
an idea of the potential of glycosylation for a lysin
of interest.
A third masking approach focuses on avoiding or
reducing the presentability of proteolytic peptides, so-
called epitopes, of lysins in MHC complexes (depletion
of T-cell epitopes). Epitopes presented in MHC com-
plexes are about 10 amino acids in length (Blum et al.
2013). Furthermore, algorithms, data transformations,
and machine learning approaches revealed MHC pep-
tide-binding domains, resulting in the development of
T-cell epitope mapping tools (El-Manzalawy et al. 2011;
Paul et al. 2015). As a result, it is possible to digest a
peptide (i.e. the lysin of interest) in silico and screen it
for potential immunogenicity using mapping tools.
Table 2. Overview of lysins evaluated in a murine model of bacteraemia.
Name Generation Target Immune response Reference
Cpl-1 1st (natural) S. pneumoniae IgG, but no IgE (Jado et al. 2003; Loeffler et al. 2003;
Harhala et al. 2018)
LysS 1st (natural) A. baumannii Not determined (Kim et al. 2020)
ClyF 2nd (chimeric) S. aureus Yes, not specified (Yang et al. 2017)
Pal 1st (natural) S. pneumoniae IgG, but no IgE (Harhala et al. 2018)
LysEF-P10 1st (natural) Enterococcus faecalis IgG, but neither IgE nor IgM (Cheng et al. 2017)
ClyV 2nd (chimeric) Streptococcus agalactiae Not determined (Huang et al. 2020)
MV-L 1st (natural) S. aureus Yes, not specified (Rashel et al. 2007)
PlySs2 (CF-301) 1st (natural) S. aureus,
S. pyogenes
Yes, not specified (Gilmer et al. 2013;
Schuch et al. 2014)
P128 2nd (chimeric) S. aureus Not determined (Channabasappa et al. 2018)
ClyS 2nd (chimeric) S. aureus Yes, not specified (Pastagia et al. 2011)
LysGH15 1st (natural) S. aureus IgG (Zhang et al. 2016)
Generation, target pathogen and the observation of an immune response are listed. An IgG/IgM response indicate the generation of neutralising antibod-
ies in the bloodstream, whereas an IgE response indicates a hypersensitivity reaction.
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Upon detection of potential immunogenic regions,
amino acids can be changed to reduce immunogenicity
with minimal changes in protein conformation. Both
aspects were incorporated into a single protein design
tool, called EpiSweep (Parker et al. 2013). A deimmuni-
zation proof-of-concept was achieved for lysostaphin
(Blazanovic et al. 2015; Zhao et al. 2015). This approach
generated variants that were less immunogenic com-
pared to wild type lysostaphin. However, these variants
also showed reduced antibacterial activity. Two lead
variants were selected: Opt4 and Lib5, the first being
less immunogenic, but also losing 99.75% of its antibac-
terial activity. In contrast, Lib5 was only slightly more
immunogenic than Opt4, but retained 50% of its anti-
bacterial activity. Using two different murine models,
Zhao and colleagues showed the deimmunization
approach to be specific for the human MHC complex,
responsible for antibody generation (Zhao et al. 2015).
One murine model expressed an endogenous murine
MHC complex, whereas the other group expressed a
chimeric human MHC complex. In mice expressing the
human MHC complex, the deimmunized lead Lib5 eli-
cited a reduced immune response, which was not the
case in mice expressing the murine MHC complex. In
addition, they showed that for a recurring bacteraemia
model in which mice are challenged and treated again
on a weekly basis, the antibody titre against both pro-
teins increased after each treatment. Since Lib5 is a less
immunogenic variant, the titre was substantially
reduced compared to titre observed in animals treated
with wild type lysostaphin. As a result, wild type lysos-
taphin treatment was unable to save any mice in a
second infection. In contrast, Lib5 treatment could res-
cue two out of three animals, which also survived a
third infection and treatment cycle. It should be noted
that the one that did not survive the second challenge,
developed antibodies in the same extent as wild type
lysostaphin (Zhao et al. 2015). With this experiment, the
potential of deimmunized variants for treatment in
recurring infections is clear. This approach has not yet
been described for other lysins but a patent describing
deimmunized variants of PlySs2 (CF-301), the lead vari-
ant of a US-based company, was filed (Schuch
et al. 2018).
Third-generation lysins to increase the lysin half-
life by reducing the renal filtration rate
Upon systemic administration, lytic enzymes appear to
be characterized by a short half-life. Indeed, individual
cases of recorded half-life to date were shown to be
20.5, 22.5, and 60min, respectively (Loeffler et al. 2003;
Walsh et al. 2003; Jun et al. 2017). The kidney plays an
important role in this regard: glomerular filtration filters
proteins smaller than 40–50 kDa into the excretion fluid
(Kontermann 2011). Since lysins are often smaller than
this cut-off value, a significant portion of therapeutic
protein is likely to be cleared from the body in this way.
Third-generation engineering approaches can address
this hurdle.
The first strategy to reduce the influence of renal fil-
tration relied on increasing the hydrodynamic volume.
By increasing the capacity to bind water molecules, par-
ticle size will increase as well. As a result, renal filtration
is hampered. Hydrodynamic volume increase can be
achieved by conjugating the lysin with water-binding
polymers such as PEG (Turecek et al. 2016). This strategy
was applied to lysostaphin leading to an increase in half-
life up to 24 h, whereas 95% of the unPEGylated enzyme
was cleared after 1 h (Walsh et al. 2003). An in-depth
analysis of the effects of PEGylation on Hen egg-white
lysozyme has been published, revealing that PEGylation
results in a two- to fourfold increase in Stokes or hydro-
dynamic radius depending on the type of PEG polymer
that was used (Gokarn et al. 2012). As such, PEGylation
could increase the half-life of lysins by acting on different
concepts: evading the immune system as was described
above and reduced glomerular filtration by increasing
the hydrodynamic volume of the particle. However, it
should be noted that this approach could result in an
inactive lysin and will impact the production efficiency
and cost of such products (Resch et al. 2011b).
A more straightforward approach to reduce glom-
erular filtration involves dimerization of the lysin. This
strategy was applied to the pneumococcal lysin Cpl-1
by introducing cysteine-residues at the C-terminus of
the lysin (Resch et al. 2011a). In this manner, stable
dimers of 74 kDa in size could be obtained, now larger
than the renal filtration cut-off (40–50 kDa), and corres-
pondingly resulting in a tenfold increased half-life.
Interestingly, applying also doubled the enzymatic
activity. This could be explained by the presence of two
catalytic sites. It should be noted that the latter was
observed in vitro only; whether this also contributes to
higher anti-pneumococcal activity in vivo should be
examined. Another approach of dimerization was fol-
lowed for the lytic bacteriocin lysostaphin. There, an
a-helical dimerization domain was used to obtain
dimeric lysostaphin. This approach resulted in a
doubled half-life, albeit a reduction in in vitro antibac-
terial activity, reflected by a 32-fold increase in min-
imum inhibitory concentration (MIC), was observed as
well (Grishin, Lavrova, et al. 2019). An in vivo experi-
ment in which systemically infected mice are treated
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with the two variants of the bacteriocin could reveal
whether the prolonged residence time of the dimeric
lysin compensates for the reduced in vitro activity.
An alternative approach was followed by Seijsing
and colleagues, relying on a fusion to an albumin-bind-
ing domain (ABD) (Seijsing et al. 2018). This 5 kDa-
domain binds albumin with high affinity, and engineer-
ing efforts increased its binding affinity (Jonsson et al.
2008). Interestingly, albumin is protected from catabolic
turnover by exploiting the FcRn pathway, resulting in a
longer half-life of the protein (Chaudhury et al. 2003).
After fusion to the ABD, the lysin will bind albumin and
be recycled by the same complex pathway, thus
increasing its half-life. Moreover, due to association
with human serum albumin, a protein of 67 kDa, a large
hydrodynamic volume is created, resulting in reduced
glomerular filtration (Chaudhury et al. 2003;
Kontermann 2011). Seijsing et al. focussed on LysK, a
lysin derived from S. aureus phage K comprising an N-
terminal CHAP domain, a central amidase-2 domain,
and a C-terminal SH3b. They incorporated the ABD at
different sites of the lysin. More specifically, they not
only made N-terminal and C-terminal fusions but also
inserted the ABD in between the CHAP and amidase-2
domain and in between the amidase-2 and the SH3b
domain. Furthermore, they also removed the amidase-2
domain, as this domain contributed little to the overall
enzymatic activity of the lysin (Becker et al. 2009). In
vitro, the engineered variant lacking the amidase-2
domain and comprising the ABD in between the CHAP
and SH3b domains showed the highest muralytic activ-
ity of all variants. This engineered variant could reduce
S. aureus numbers by three log units within an hour in
a time-kill assay, while a control lacking the ABD
resulted in a four-log unit reduction of the bacterial
count. However, an in vivo experiment revealed the
added value of the ABD. Whereas the half-life of the
CHAP-SH3b construct was 23 h, the engineered variant
had a half-life of 34 h (Seijsing et al. 2018).
Subsequently, the enzyme can exert its (slightly lower)
antibacterial activity for a longer period of time, poten-
tially enhancing its antibacterial effect. The same
approach was used to successfully extend the half-life
of lysostaphin (Grishin, Shestak, et al. 2019).
The effects of these interesting engineering efforts
prolonging the half-life are tested in a murine model,
but differences may exist between different test organ-
isms. As an example, lysin SAL-200 showed a rather
long half-life in monkeys (up to 9 h) whereas the half-
life in humans was short (maximal 0.38 h) (Jun et al.
2016, 2017). Nonetheless, the potential of these
approaches is clear despite this translational hurdle.
Conclusion & future perspectives
Over the past decade, the potential of lysins in fighting
emerging antibiotic resistance has become clear. Due
to their rapid action, anti-persister activity, recalcitrance
towards resistance development and progress in clinical
trials, lysins have been proposed as a highly promising
alternative class of new antibacterials (Briers, Walmagh,
Grymonprez, et al. 2014; Gutierrez et al. 2014;
Czaplewski et al. 2016; Defraine et al. 2016).
Furthermore, these new antibacterials also show syner-
gies with a currently used standard of care antibiotics,
enabling the possibility of combination therapies
(Channabasappa et al. 2018; Kim et al. 2018; Watson
et al. 2019). First- and second-generation lysins may
encounter specific hurdles or may perform suboptimally
under clinical settings, giving room for further optimiza-
tions. These opportunities are increasingly explored by
advanced engineering techniques, defined here as
third-generation lysins, and formulation strategies. This
potential for easy engineering sets lysins apart from all
existing classes of small-molecule antibiotics.
This review discussed approaches to tackle clinical
hurdles. Briefly, one can expand the activity of a lysin
by fusion to cell-penetrating peptides to target intracel-
lular pathogens, co-formulate the lysin with anti-inflam-
matory compounds, or with polymers having beneficial
properties for topical applications. In addition, the half-
life can be increased by reducing the risk of an immune
response using so-called masking-strategies or by
avoiding renal filtration increasing the hydrodynamic
volume. Several of these engineering efforts resulted in
reduced antibacterial activity in vitro, however, the
added value became clear when tested in vivo. For
example, by increasing their half-life by deimmuniza-
tion, third-generation lysins performed worse in vitro
but were shown to be more effective to treat recurrent
infections in vivo (Zhao et al. 2015). Another example is
the fusion with cell-penetrating peptides (CPPs). Here,
the reduction in antibacterial activity was compensated
by targeting intracellular S. aureus thereby eradicating a
major cause of recurrent, chronic infections (Wang et al.
2018; R€ohrig et al. 2020).
All efforts discussed in this review involved enzymes
targeting Gram-positive pathogens. Indeed, it is even
more challenging to come up with an efficient lysin-
based approach to combat Gram-negative pathogens
as the peptidoglycan layer is shielded by an outer
membrane. Nonetheless, several second-generation
lysins have (recently) shown to be promising against
Gram-negative bacteria in vitro and ex vivo. A few engi-
neered lysins have shown efficacy in C. elegans and
mice (Briers, Walmagh, Van Puyenbroeck, et al. 2014;
CRITICAL REVIEWS IN MICROBIOLOGY 11
Heselpoth et al. 2019). Furthermore, two case studies
with Art-175 in dogs have been reported (Briers and
Lavigne 2015). Third-generation engineering
approaches should be considered in the further devel-
opment of these lysins targeting Gram-negative patho-
gens as well.
Generation of a lysin possessing superior properties
might be facilitated using libraries with increased com-
plexity combined with a screening approach under rele-
vant conditions. This was illustrated by R€ohrig and
colleagues who performed a preceding screening of
enzyme variants under intracellular and lysosomal con-
ditions before different fusions with CPPs were
attempted (R€ohrig et al. 2020). Whereas the authors
could rely on an available library, the VersaTile
approach (Gerstmans et al. 2020) could further leverage
this process by increasing library complexity by incor-
porating more CPPs, more CBDs, EADs, or other ele-
ments of interest. It is clear that many concepts that are
highlighted in this review can benefit from such libra-
ries of increased complexity, but following the first law
of directed evolution (“you get what you screen for”),
the screening assays must be carefully selected and/or
combined given the observed discrepancies between
different in vitro and in vivo assays (Schmidt-Dannert
and Arnold 1999; Peisajovich and Tawfik 2007).
Several third-generation engineering strategies or
formulation strategies discussed in this review (Figure
2, Table 1) can be expanded to combat infections in
other body sites. As mentioned before, a limited
amount of third-generation approaches or formulation
strategies have been reported for some mucosal appli-
cations. As an example, one might also consider the
use of nanoparticles to increase the release time of lysin
to fight urinary tract, vaginal, or other mucosa-related
infections. Indeed, both liposomal and niosome nano-
particle formulation strategies with lysins may have the
potential to combat these types of infections (Bai et al.
2019; Sadeghi et al. 2019; Portilla et al. 2020). In gen-
eral, literature describing the treatment of these infec-
tions with lysins is rather limited notwithstanding there
is a high societal need for alternatives to the current
small-molecule antibiotics (Cheng et al. 2005; Li
et al. 2018).
As lysins are moving closer towards actual introduc-
tion in the clinic, limited protein yield in standard
industrial expression systems might represent an add-
itional hurdle for translation to practice. Therefore,
some suggested third-generation approaches might be
less favourable. As an example, one could opt to glyco-
sylate the therapeutic protein to reduce proteolysis
in vivo (Doering et al. 2017). However, eukaryotic
expression systems are cost-intensive, and apart from
yeast-based expression systems less scalable.
Two decades of research of lysins as antibacterials
have resulted in substantial progress, with a growing
global community of researchers from an increasing
number of disciplines involved. It is expected that inter-
disciplinary approaches will further leverage lysins as a
class of novel antibiotics. In addition, lysins can be eas-
ily modified and fused with function enhancing
domains due to their proteinaceous and modular
nature, giving rise to a distinct engineering potential.
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